Lb Pharmaceuticals (LBRX) Common Equity (2024 - 2026)

Lb Pharmaceuticals' Common Equity history runs 3 years deep, the most recent figure standing at $378.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 481.22% year-over-year to $378.7 million; the TTM figure through Mar 2026 stood at $378.7 million (up 481.22% YoY), while the FY2025 annual figure was $301.3 million, up 418.66% from the prior year.
• Common Equity for Q1 2026 stood at $378.7 million, up from $301.3 million in the prior quarter.
• The five-year high for Common Equity was $378.7 million in Q1 2026, with the low at -$99.3 million in Q1 2025.
• The 3-year median for Common Equity is $104.9 million (2024), against an average of $117.5 million.
• The sharpest annual moves came in 2025 and 2026: Common Equity jumped 418.66% in 2025, then surged 481.22% in 2026.
• Lb Pharmaceuticals' Common Equity stood at -$94.6 million in 2024, then surged by 418.66% to $301.3 million in 2025, then increased by 25.68% to $378.7 million in 2026.
• Business Quant data shows LBRX's Common Equity at $378.7 million in Q1 2026, $301.3 million in Q4 2025, and $310.2 million in Q3 2025.